Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2016-02-17 Interim / Quarterly Rep…
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Half Year Report and Accounts 22 pages 1.2MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR REPORT' and references a 'Consolidated Half-Year Report and associated results announcement' for the half-year ended 31 December 2015. It contains detailed financial results including revenue, profit, cash balances, EPS, and net tangible assets, as well as operational highlights, clinical developments, and strategic outlook. The document includes a Chairman’s and CEO’s report, key performance highlights, and a dividend declaration. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. The presence of detailed financial statements and management discussion for a half-year period clearly identifies this as an Interim / Quarterly Report rather than a brief announcement or other filing type. H1 2016
2016-02-17 English
Dividend/Distribution - MVP 4 pages 34.9KB
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Notification of dividend / distribution' and contains detailed information about a dividend payment by Medical Developments International Limited. It includes the dividend amount, ex-date, record date, payment date, and details about the Dividend Reinvestment Plan (DRP). The content is focused on announcing the dividend specifics to shareholders rather than providing a full financial report or analysis. This matches the definition of a 'Notice of Dividend Amount' filing, which announces dividend amounts, payment dates, and related details for shareholders.
2016-02-17 English
MVP Completes Acquisition of Breath-A-Tech 2 pages 206.4KB
M&A Activity Classification · 95% confidence The document is an ASX announcement dated 5 February 2016 about the completion of an acquisition by Medical Developments International Limited (MVP) of Breath-A-Tech. It details the acquisition terms including cash and share consideration, and includes statements from the CEO about the strategic impact of the acquisition. There are no financial statements, quarterly or annual results, or regulatory certifications. The content is clearly an announcement of a merger/acquisition event rather than a full merger filing or proxy statement. Therefore, the document fits best under the category for M&A Activity announcements.
2016-02-04 English
Appendix 3B 12 pages 525.7KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new shares, including the number of shares issued, issue price, terms, and compliance with ASX listing rules. It includes sections on placement capacity calculations under ASX rules 7.1 and 7.1A, which relate to the company's ability to issue new securities without shareholder approval. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new share issue and application for quotation of additional securities. It is not a financial report, earnings release, or management discussion, but a regulatory announcement about capital raising and share issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement. Confidence is high due to the clear and specific nature of the document.
2016-02-04 English
CEO UK Roadshow Presentation 24 pages 2.0MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Medical Developments International for a UK Road Show in February 2016. It extensively discusses the company's products, market strategy, regulatory progress, intellectual property, manufacturing, sales, and management team. The content is focused on providing investors and stakeholders with an overview of the company's business opportunities, product advantages, market potential, and future plans. There are no financial statements, audit opinions, or regulatory certifications present. The document is not a formal annual or interim report, nor is it a transcript of a call or a legal filing. It fits the profile of an Investor Presentation, which typically includes strategic and financial highlights aimed at investors and analysts. The length (15,000 characters) and detailed content support this classification rather than a brief announcement or a regulatory filing.
2016-02-02 English
Penthrox Launch in the UK and Pricing Approval for Ireland 2 pages 208.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 27 January 2016 regarding the launch of a product (Penthrox) in the UK and pricing approval in Ireland. It contains no financial statements, no detailed financial data, no regulatory certifications, or voting results. It is a business update about product launch and pricing approval, which fits best under a general regulatory announcement category. The document length is under 5,000 characters and it is an announcement rather than a full report or detailed presentation. Therefore, it should be classified as a Regulatory Filing (RNS).
2016-01-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.